Geode Capital Management’s Gyre Therapeutics GYRE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.01M Buy
431,414
+8,192
+2% +$63.6K ﹤0.01% 2969
2025
Q4
$2.99M Buy
423,222
+48,602
+13% +$375K ﹤0.01% 3013
2025
Q3
$2.8M Sell
374,620
-27,089
-7% -$206K ﹤0.01% 3068
2025
Q2
$2.95M Buy
401,709
+89,390
+29% +$780K ﹤0.01% 2999
2025
Q1
$2.41M Buy
312,319
+8,221
+3% +$90.2K ﹤0.01% 2969
2024
Q4
$3.68M Buy
304,098
+451
+0.1% +$5.77K ﹤0.01% 2891
2024
Q3
$3.81M Buy
303,647
+43,840
+17% +$565K ﹤0.01% 2898
2024
Q2
$3.1M Buy
259,807
+99,218
+62% +$1.36M ﹤0.01% 2967
2024
Q1
$2.81M Buy
160,589
+26,164
+19% +$472K ﹤0.01% 2982
2023
Q4
$3.45M Buy
134,425
+117,175
+679% +$1.66M ﹤0.01% 2882
2023
Q3
$125K Sell
17,250
-752
-4% -$5.04K ﹤0.01% 4167
2023
Q2
$94.9K Hold
18,002
﹤0.01% 4351
2023
Q1
$55.9K Sell
18,002
-18,610
-51% -$70.7K ﹤0.01% 4493
2022
Q4
$144K Sell
36,612
-90
-0.2% -$367 ﹤0.01% 4249
2022
Q3
$138K Hold
36,702
﹤0.01% 4400
2022
Q2
$489K Sell
36,702
-3,191
-8% -$21.2K ﹤0.01% 3779
2022
Q1
$197K Buy
39,893
+1,682
+4% +$8.34K ﹤0.01% 4391
2021
Q4
$261K Sell
38,211
-8,661
-18% -$148K ﹤0.01% 4361
2021
Q3
$1.44M Buy
46,872
+2,541
+6% +$83.6K ﹤0.01% 3503
2021
Q2
$1.44M Sell
44,331
-26,919
-38% -$924K ﹤0.01% 3423
2021
Q1
$2.69M Buy
71,250
+28,940
+68% +$1.32M ﹤0.01% 3113
2020
Q4
$2M Buy
42,310
+4,174
+11% +$181K ﹤0.01% 3084
2020
Q3
$1.23M Buy
38,136
+5,815
+18% +$228K ﹤0.01% 3127
2020
Q2
$1.42M Buy
32,321
+16,499
+104% +$775K ﹤0.01% 3020
2020
Q1
$518K Buy
15,822
+1,610
+11% +$74K ﹤0.01% 3264
2019
Q4
$725K Hold
14,212
﹤0.01% 3388
2019
Q3
$523K Buy
14,212
+1,826
+15% +$98.4K ﹤0.01% 3461
2019
Q2
$684K Sell
12,386
-5,997
-33% -$375K ﹤0.01% 3349
2019
Q1
$1.12M Sell
18,383
-840
-4% -$54K ﹤0.01% 3124
2018
Q4
$1.14M Buy
19,223
+720
+4% +$53.1K ﹤0.01% 3050
2018
Q3
$1.5M Sell
18,503
-3,755
-17% -$298K ﹤0.01% 3040
2018
Q2
$1.95M Buy
22,258
+13,888
+166% +$2.44M ﹤0.01% 2875
2018
Q1
$1.62M Buy
8,370
+4,663
+126% +$870K ﹤0.01% 2876
2017
Q4
$379K Buy
+3,707
New +$189K ﹤0.01% 3462
2017
Q3
Sell
-1,658
Closed -$57K 4062
2017
Q2
$57K Buy
+1,658
New +$59.5K ﹤0.01% 3930
2017
Q1
Sell
-229
Closed -$16K 4076
2016
Q4
$16K Buy
229
+1
+0.4% +$90 ﹤0.01% 4015
2016
Q3
$31K Hold
228
﹤0.01% 3964
2016
Q2
$39K Hold
228
﹤0.01% 3961
2016
Q1
$43 Hold
228
﹤0.01% 3986
2015
Q4
$80K Hold
228
﹤0.01% 3932
2015
Q3
$119K Hold
228
﹤0.01% 3850
2015
Q2
$500K Hold
228
﹤0.01% 3198
2015
Q1
$532K Hold
228
﹤0.01% 3171
2014
Q4
$471K Buy
228
+1
+0.4% +$1.93K ﹤0.01% 3217
2014
Q3
$452K Buy
227
+6
+3% +$14.8K ﹤0.01% 3217
2014
Q2
$783K Sell
221
-25
-10% -$81.6K ﹤0.01% 2941
2014
Q1
$921K Buy
246
+5
+2% +$18.5K ﹤0.01% 2846
2013
Q4
$788K Hold
241
﹤0.01% 2862
2013
Q3
$1.01M Buy
241
+11
+5% +$44.3K ﹤0.01% 2586
2013
Q2
$774K Buy
+230
New +$875K ﹤0.01% 2614

Other funds holding GYRE

Geode Capital Management's GYRE Position: Q1 2026 in Review

Geode Capital Management increased its Gyre Therapeutics (GYRE) stake by 1.9% in Q1 2026, buying an estimated $63.6K and bringing the position to 431,414 shares worth $3.01M. The position accounts for ﹤0.01% of the portfolio, ranked #2969.

Geode Capital Management first reported a position in GYRE in Q2 2013 and has held it in 50 quarters since. The position peaked at $3.81M in Q3 2024. 56 funds tracked by Wall St. Rank hold GYRE as of Q1 2026.

  • Geode Capital Management held 431,414 shares of Gyre Therapeutics worth $3.01M as of Q1 2026.
  • Geode Capital Management bought 8,192 Gyre Therapeutics shares in Q1 2026, an estimated $63.6K.
  • Gyre Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #2969 holding.
  • Geode Capital Management first reported a position in Gyre Therapeutics in Q2 2013 and has held it in 50 quarters since.
  • Geode Capital Management's Gyre Therapeutics position peaked at $3.81M in Q3 2024.
  • 56 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.